Live feed06:00:00·1722dPRReleasevia QuantisnowSyndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic DiseasesByQuantisnow·Wall Street's wire, on your screen.INCY· Incyte Corp.SNDX· Syndax Pharmaceuticals Inc.Health Care